US OptionsDetailed Quotes
CHRS241220C500
- 1.08
- 0.000.00%
15min DelayClose Dec 13 16:00 ET
0.00High0.00Low
1.08Open1.08Pre Close0 Volume11 Open Interest0.50Strike Price0.00Turnover1219.93%IV-1.86%PremiumDec 20, 2024Expiry Date1.11Intrinsic Value100Multiplier6DDays to Expiry0.00Extrinsic Value100Contract SizeAmericanOptions Type0.9372Delta0.0476Gamma1.26Leverage Ratio-0.0263Theta0.0000Rho1.18Eff Leverage0.0003Vega
Coherus BioSciences Stock Discussion
Sign in to post a comment
Note: The presence of 30 stock picks reflects the reality that not all stocks respond to their press releases immediately. For instance, today’s market activity saw certain high-performing stocks overshadow promising PRs, suggesting that it may take a day, several days, or even a week for the market to fully digest and react. I encourage you to save the watchlist I p...
34
7
6
$Coherus BioSciences (CHRS.US)$ sucks, not looking good anymore
1
$Coherus BioSciences (CHRS.US)$ bullish finally
2
$Coherus BioSciences (CHRS.US)$ once the shorters got squeeze, easily $4. All in now before its too late.
1
![[undefined]](https://static.moomoo.com/nnq/emoji/static/image/default/default-black.png?imageMogr2/thumbnail/36x36 "undefined"){kind=small}
$Coherus BioSciences (CHRS.US)$
Coherus Announces Agreement to Divest UDENYCA® Franchise for up to $558 million to Intas Pharmaceuticals Ltd.
7 minutes ago, 4:00 AM PST
Via GlobeNewswire
CHRS
Share
- Coherus to focus exclusively on innovative immuno-oncology programs that include LOQTORZI®, an FDA approved, next-generation programmed cell death protein 1 (PD-1) inhibitor -
- Proceeds to fund development of key combination programs with LOQTORZI, including casdozokitug, a first-in-class, cli...
Coherus Announces Agreement to Divest UDENYCA® Franchise for up to $558 million to Intas Pharmaceuticals Ltd.
7 minutes ago, 4:00 AM PST
Via GlobeNewswire
CHRS
Share
- Coherus to focus exclusively on innovative immuno-oncology programs that include LOQTORZI®, an FDA approved, next-generation programmed cell death protein 1 (PD-1) inhibitor -
- Proceeds to fund development of key combination programs with LOQTORZI, including casdozokitug, a first-in-class, cli...
1
No comment yet
AhmadFH : Thanks Jag
71580478 : love it, thanks! what do you think about SHIM?
JMK47 : thanks for all your effort
101628821 : Is it going to melt or continue to rise today?
101821671 : Do you have any opinions on the stock symbol SOAR?
View more comments...